C Jones, P Dutey-Magni, L R Murphy, M L Murray, J E Brown, E McCloskey, M Brown, C L Amos, D C Gilbert, R J Jones, W Cross, D Matheson, R Millman, M K B Parmar, G Attard, M R Sydes, L C Brown, N D James, N W Clarke, A Sachdeva
{"title":"新诊断的高风险局部或转移性激素敏感前列腺癌中骨折相关住院：使用医疗系统数据对STAMPEDE多西他赛和唑来膦酸3期试验的二次分析","authors":"C Jones, P Dutey-Magni, L R Murphy, M L Murray, J E Brown, E McCloskey, M Brown, C L Amos, D C Gilbert, R J Jones, W Cross, D Matheson, R Millman, M K B Parmar, G Attard, M R Sydes, L C Brown, N D James, N W Clarke, A Sachdeva","doi":"10.1016/j.annonc.2025.07.005","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Androgen deprivation therapy (ADT), the mainstay systemic treatment for high risk non-metastatic (M0) and metastatic (M1) prostate cancer (PCa) is associated with bone loss and increased fracture risk. The STAMPEDE trial tested the addition of zoledronic acid ± docetaxel (with prednisolone) to ADT. Both regimens may impact bone health. However, long-term fracture incidence remains uncertain.</p><p><strong>Patients and methods: </strong>Health systems data were obtained for pts recruited from England and randomised to standard-of-care (SOC) ADT compared with SOC plus zoledronic acid or docetaxel or both docetaxel and zoledronic acid. ICD10 diagnosis and OPCS procedure codes from inpatient hospital admissions were used to identify fracture-related hospitalisations (FRH). Flexible parametric competing risks models were used to estimate 5- and 10-year cumulative incidence and sub-distribution hazard ratios (SDHR).</p><p><strong>Results: </strong>2,140 of 2,705 (79%) pts recruited from trial sites in England were eligible for this secondary analysis. Linked data were available for 2,042/2,140 (96%) pts (734 M0, 1,308 M1). 5-year cumulative incidence of fracture for M0 and M1 pts treated with SOC only was 11% (95% CI, 8-15%) and 23% (95% CI, 19-28%) respectively. 10-year cumulative incidence in M0 pts was 26% (95% CI, 20-33%). Allocation to zoledronic acid significantly reduced the risk of fracture in M1 pts (SDHR 0.73, 95% CI 0.55-0.97; p=0.015) but not M0 pts (SDHR 0.88, 95% CI 0.59-1.32; p=0.549). Docetaxel had no clear effect on the risk of fracture in M0 (p=0.570) or M1 (p=0.264) pts.</p><p><strong>Conclusions: </strong>High cumulative incidence of fracture was observed in both non-metastatic and metastatic PCa patients receiving ADT. The addition of zoledronic acid to ADT ± docetaxel significantly reduced long-term fracture risk in metastatic participants but had no clear effect in non-metastatic disease. These data support the use of bone protective agents to reduce fracture risk in men with metastatic prostate cancer undergoing ADT.</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":56.7000,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase 3 trials of docetaxel and zoledronic acid using healthcare systems data.\",\"authors\":\"C Jones, P Dutey-Magni, L R Murphy, M L Murray, J E Brown, E McCloskey, M Brown, C L Amos, D C Gilbert, R J Jones, W Cross, D Matheson, R Millman, M K B Parmar, G Attard, M R Sydes, L C Brown, N D James, N W Clarke, A Sachdeva\",\"doi\":\"10.1016/j.annonc.2025.07.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Androgen deprivation therapy (ADT), the mainstay systemic treatment for high risk non-metastatic (M0) and metastatic (M1) prostate cancer (PCa) is associated with bone loss and increased fracture risk. The STAMPEDE trial tested the addition of zoledronic acid ± docetaxel (with prednisolone) to ADT. Both regimens may impact bone health. However, long-term fracture incidence remains uncertain.</p><p><strong>Patients and methods: </strong>Health systems data were obtained for pts recruited from England and randomised to standard-of-care (SOC) ADT compared with SOC plus zoledronic acid or docetaxel or both docetaxel and zoledronic acid. ICD10 diagnosis and OPCS procedure codes from inpatient hospital admissions were used to identify fracture-related hospitalisations (FRH). Flexible parametric competing risks models were used to estimate 5- and 10-year cumulative incidence and sub-distribution hazard ratios (SDHR).</p><p><strong>Results: </strong>2,140 of 2,705 (79%) pts recruited from trial sites in England were eligible for this secondary analysis. Linked data were available for 2,042/2,140 (96%) pts (734 M0, 1,308 M1). 5-year cumulative incidence of fracture for M0 and M1 pts treated with SOC only was 11% (95% CI, 8-15%) and 23% (95% CI, 19-28%) respectively. 10-year cumulative incidence in M0 pts was 26% (95% CI, 20-33%). Allocation to zoledronic acid significantly reduced the risk of fracture in M1 pts (SDHR 0.73, 95% CI 0.55-0.97; p=0.015) but not M0 pts (SDHR 0.88, 95% CI 0.59-1.32; p=0.549). Docetaxel had no clear effect on the risk of fracture in M0 (p=0.570) or M1 (p=0.264) pts.</p><p><strong>Conclusions: </strong>High cumulative incidence of fracture was observed in both non-metastatic and metastatic PCa patients receiving ADT. The addition of zoledronic acid to ADT ± docetaxel significantly reduced long-term fracture risk in metastatic participants but had no clear effect in non-metastatic disease. These data support the use of bone protective agents to reduce fracture risk in men with metastatic prostate cancer undergoing ADT.</p>\",\"PeriodicalId\":8000,\"journal\":{\"name\":\"Annals of Oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":56.7000,\"publicationDate\":\"2025-07-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.annonc.2025.07.005\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.annonc.2025.07.005","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase 3 trials of docetaxel and zoledronic acid using healthcare systems data.
Background: Androgen deprivation therapy (ADT), the mainstay systemic treatment for high risk non-metastatic (M0) and metastatic (M1) prostate cancer (PCa) is associated with bone loss and increased fracture risk. The STAMPEDE trial tested the addition of zoledronic acid ± docetaxel (with prednisolone) to ADT. Both regimens may impact bone health. However, long-term fracture incidence remains uncertain.
Patients and methods: Health systems data were obtained for pts recruited from England and randomised to standard-of-care (SOC) ADT compared with SOC plus zoledronic acid or docetaxel or both docetaxel and zoledronic acid. ICD10 diagnosis and OPCS procedure codes from inpatient hospital admissions were used to identify fracture-related hospitalisations (FRH). Flexible parametric competing risks models were used to estimate 5- and 10-year cumulative incidence and sub-distribution hazard ratios (SDHR).
Results: 2,140 of 2,705 (79%) pts recruited from trial sites in England were eligible for this secondary analysis. Linked data were available for 2,042/2,140 (96%) pts (734 M0, 1,308 M1). 5-year cumulative incidence of fracture for M0 and M1 pts treated with SOC only was 11% (95% CI, 8-15%) and 23% (95% CI, 19-28%) respectively. 10-year cumulative incidence in M0 pts was 26% (95% CI, 20-33%). Allocation to zoledronic acid significantly reduced the risk of fracture in M1 pts (SDHR 0.73, 95% CI 0.55-0.97; p=0.015) but not M0 pts (SDHR 0.88, 95% CI 0.59-1.32; p=0.549). Docetaxel had no clear effect on the risk of fracture in M0 (p=0.570) or M1 (p=0.264) pts.
Conclusions: High cumulative incidence of fracture was observed in both non-metastatic and metastatic PCa patients receiving ADT. The addition of zoledronic acid to ADT ± docetaxel significantly reduced long-term fracture risk in metastatic participants but had no clear effect in non-metastatic disease. These data support the use of bone protective agents to reduce fracture risk in men with metastatic prostate cancer undergoing ADT.
期刊介绍：
Annals of Oncology, the official journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology, offers rapid and efficient peer-reviewed publications on innovative cancer treatments and translational research in oncology and precision medicine.
The journal primarily focuses on areas such as systemic anticancer therapy, with a specific emphasis on molecular targeted agents and new immune therapies. We also welcome randomized trials, including negative results, as well as top-level guidelines. Additionally, we encourage submissions in emerging fields that are crucial to personalized medicine, such as molecular pathology, bioinformatics, modern statistics, and biotechnologies. Manuscripts related to radiotherapy, surgery, and pediatrics will be considered if they demonstrate a clear interaction with any of the aforementioned fields or if they present groundbreaking findings.
Our international editorial board comprises renowned experts who are leaders in their respective fields. Through Annals of Oncology, we strive to provide the most effective communication on the dynamic and ever-evolving global oncology landscape.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
